Commencez
ReutersReuters

Oncolytics Biotech® Aligns With FDA On Pivotal Study Design For Pelareorep In First-Line Pancreatic Cancer

RefinitivMoins d'1 minute de lecture
ONCY

Oncolytics Biotech Inc ONCY:

  • ONCOLYTICS BIOTECH® ALIGNS WITH FDA ON PIVOTAL STUDY DESIGN FOR PELAREOREP IN FIRST-LINE PANCREATIC CANCER

  • ONCOLYTICS BIOTECH INC - TO LAUNCH IMMUNOTHERAPY TRIAL IN PANCREATIC CANCER IN 2026

Actions américainesActions canadiennesReuters
© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html
Connectez-vous ou créez un compte gratuit à vie pour lire ces nouvelles

Plus de nouvelles provenant de Reuters